1,023 research outputs found
Metastatic melanoma cells with BRAF G469A mutation: nab‑paclitaxel better than vemurafenib?
Purpose BRAF G469A is a missense mutation within
exon 11 of the BRAF gene resulting in a constitutively
activated enzyme frequently associated with MAP kinase
cascade signaling activation. No evidence currently exists
about its role in determining sensitivity/resistance to BRAF
inhibitors, utilized in the treatment of patients carrying
BRAF V600 mutations, and to chemotherapy. The newly
established metastatic melanoma (MM) cell line MO-1 was
characterized for its sensitivity to vemurafenib and nabpaclitaxel, both already utilized for the treatment of MM.
Methods All analyses were carried out by comparing
results with those found in MM cells wild type for BRAF
or mutated in V600. In addition, cellular effectors were
investigated by ELISA kits, western blotting and flow
cytometry.
Results The exposure to vemurafenib inhibited MO-1 cell
proliferation at concentrations similar to those obtained in
vemurafenib-resistant melanoma models, and an explanation of this sensitivity is the strong activation of Erk1/2 .
and the low expression of MITF. Nab-paclitaxel strongly
reduced proliferation of MO-1 cells perhaps for the very
low expression level of PMEL17, transcriptionally regulated by MITF and negatively involved in determining sensitivity to taxanes.
Conclusions Thus, the mutation BRAF G469A in MM
might be related to a weak effectiveness of therapy with
BRAF inhibitors and a promising therapeutic approach
may be with nab-paclitaxel
Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib
The crosstalk between Notch and MAPK pathway plays a role in MEK inhibitor resistance in BRAFV600E metastatic
melanoma (MM) and promotes migration in GNAQQ209L uveal melanoma (UM) cells. We determined the
cytotoxicity of combinatorial inhibition of MEK and Notch by cobimetinib and Îł-secretase inhibitor (GSI) nirogacestat,
in BRAFV600E and BRAF wt MM and GNAQQ209L UM cells displaying different Erk1/2 and Notch
activation status, with the aim to elucidate the impact of Notch signaling in the response to MEK inhibitor.
Overall the combination was synergic in BRAFV600E MM and GNAQQ209L UM cells and antagonistic in BRAF wt
one. Focusing on UM cells, we found that cobimetinib resulted in G0/G1 phase arrest and apoptosis induction,
whereas the combination with GSI increased treatment efficacy by inducing a senescent-like state of cells and by
blocking migration towards liver cancer cells. Mechanistically, this was reflected in a strong reduction of cyclin
D1, in the inactivation of retinoblastoma protein and in the increase of p27KIP1 expression levels. Of note, each
drug alone prevented Notch signaling activation resulting in inhibition of c-jun(Ser63) and Hes-1 expression. The
combination achieved the strongest inhibition on Notch signaling and on both c-jun(Ser63) and Erk1/2 activation
level. In conclusion we unveiled a coordinate action of MAPK and Notch signaling in promoting proliferation
of BRAFV600E MM and GNAQQ209L UM cells. Remarkably, the simultaneous inhibition of MEK and Notch
signaling highlighted a role for the second pathway in protecting cells against senescence in GNAQQ209L UM cells
treated with the MEK inhibitor
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy
Background: The poor response to chemotherapy and the brief response to vemurafenib in metastatic melanoma patients, make the identification of new therapeutic approaches an urgent need. Interestingly the increased expression and activity of the Aurora kinase B during melanoma progression suggests it as a promising therapeutic target. Methods: The efficacy of the Aurora B kinase inhibitor barasertib-HQPA was evaluated in BRAF mutated cells, sensitive and made resistant to vemurafenib after chronic exposure to the drug, and in BRAF wild type cells. The drug effectiveness has been evaluated as cell growth inhibition, cell cycle progression and cell migration. In addition, cellular effectors of drug resistance and response were investigated. Results: The characterization of the effectors responsible for the resistance to vemurafenib evidenced the increased expression of MITF or the activation of Erk1/2 and p-38 kinases in the newly established cell lines with a phenotype resistant to vemurafenib. The sensitivity of cells to barasertib-HQPA was irrespective of BRAF mutational status. Barasertib-HQPA induced the mitotic catastrophe, ultimately causing apoptosis and necrosis of cells, inhibited cell migration and strongly affected the glycolytic metabolism of cells inducing the release of lactate. In association i) with vemurafenib the gain in effectiveness was found only in BRAF(V600K) cells while ii) with nab-paclitaxel, the combination was more effective than each drug alone in all cells. Conclusions: These findings suggest barasertib as a new therapeutic agent and as enhancer of chemotherapy in metastatic melanoma treatment
The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
N.A
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Background: The immunotherapy with immune checkpoints inhibitors (ICI) has changed the life expectancy in
metastatic melanoma (MM) patients. Nevertheless, several patients do not respond hence, the identifcation and
validation of novel biomarkers of response to ICI is of crucial importance. Circulating extracellular vesicles (EVs) such as
PD-L1+ EV mediate resistance to anti-PD1, instead the role of PD1+ EV is not fully understood.
Methods: We isolated the circulating EVs from the plasma of an observational cohort study of 71 metastatic melanoma patients and correlated the amount of PD-L1+ EVs and PD1+ EVs with the response to ICI. The analysis was
performed according to the origin of EVs from the tumor and the immune cells. Subsequently, we analysed the data
in a validation cohort of 22 MM patients to assess the reliability of identifed EV-based biomarkers. Additionally we
assessed the involvement of PD1+ EVs in the seizure of nivolumab and in the perturbation of immune cells-mediated
killing of melanoma spheroids.
Results: The level of PD-L1+ EVs released from melanoma and CD8+ T cells and that of PD1+ EVs irrespective of the
cellular origin were higher in non-responders. The Kaplan-Meier curves indicated that higher levels of PD1+ EVs were
signifcantly correlated with poorer progression-free survival (PFS) and overall survival (OS). Signifcant correlations
were found for PD-L1+ EVs only when released from melanoma and T cells. The multivariate analysis showed that
high level of PD1+ EVs, from T cells and B cells, and high level of PD-L1+ EVs from melanoma cells, are independent
biomarkers of response. The reliability of PD-L1+ EVs from melanoma and PD1+ EVs from T cells in predicting PFS was
confrmed in the validation cohort through the univariate Cox-hazard regression analysis. Moreover we discovered
that the circulating EVs captured nivolumab and reduced the T cells trafcking and tumor spheroids killing.
Conclusion: Our study identifed circulating PD1+ EVs as driver of resistance to anti-PD1, and highlighted that the
analysis of single EV population by liquid biopsy is a promising tool to stratify MM patients for immunotherapy
Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview
Colorectal carcinoma is the second leading cause of cancer-related deaths, and indeed, rectal cancer accounting for approximately one third of newly diagnosed patients. Gold standard in the treatment of rectal cancer is a multimodality approach, aiming at a good control of the local disease. Distant recurrences are the major cause of mortality. Currently, Locally Advanced Rectal Cancer (LARC) patients undergo a combined treatment of chemotherapy and radiotherapy, followed by surgery. Eventually, more chemotherapy, namely adjuvant chemotherapy (aCT), may be necessary. Total Neoadjuvant Therapy (TNT) is an emerging approach aimed to reduce distant metastases and improve local control. Several ongoing studies are analyzing whether this new approach could improve oncological outcomes. Published results were encouraging, but the heterogeneity of protocols in use, makes the comparison and interpretation of data rather complex. One of the major concerns regarding TNT administration is related to its effect on larger and more advanced cancers that might not undergo similar down-staging as smaller, early-stage tumors. This minireview, based on a systematic literature search of randomized clinical trials and meta-analysis, summarizes current knowledge on TNT. The aim was to confirm or refute whether or not current practice of TNT is based on relevant evidence, to establish the quality of that evidence, and to address any uncertainty or variation in practice that may be occurring. A tentative grouping of general study characteristics, clinical features and treatments characteristics has been undertaken to evaluate if the reported studies are sufficiently homogeneous in terms of subjects involved, interventions, and outcomes to provide a meaningful idea of which patients are more likely to gain from this treatment
Tissue- and Cell Type-Specific Expression of the Long Noncoding RNA Klhl14-AS in Mouse
lncRNAs are acquiring increasing relevance as regulators in a wide spectrum of biological processes. The extreme heterogeneity in the mechanisms of action of these molecules, however, makes them very difficult to study, especially regarding their molecular function. A novel lncRNA has been recently identified as the most enriched transcript in mouse developing thyroid. Due to its genomic localization antisense to the protein-encoding Klhl14 gene, we named it Klhl14-AS. In this paper, we highlight that mouse Klhl14-AS produces at least five splicing variants, some of which have not been previously described. Klhl14-AS is expressed with a peculiar pattern, characterized by diverse relative abundance of its isoforms in different mouse tissues. We examine the whole expression level of Klhl14-AS in a panel of adult mouse tissues, showing that it is expressed in the thyroid, lung, kidney, testis, ovary, brain, and spleen, although at different levels. In situ hybridization analysis reveals that, in the context of each organ, Klhl14-AS shows a cell type-specific expression. Interestingly, databases report a similar expression profile for human Klhl14-AS. Our observations suggest that this lncRNA could play cell type-specific roles in several organs and pave the way for functional characterization of this gene in appropriate biological contexts
The mitochondrial master regulator gene PGC1alpha in novel sporadic melanoma cell lines: correlations with BRAF mutational status
The RPC system for the CMS experiment at the LHC
The CMS detector at the LHC has a redundant muon system. Two independent muon systems are used in the L1 trigger. One of them is based on wire chambers, the other on RPC detectors. Properly combining the answers of the two systems results in a highly efficient L1 trigger with high flexibility from the point of view of rate control. Simulation results show, however, that the RPC system suffers from false triggers caused by coincidence of spurious hits. System improvements, which could avoid oiling the chambers, are possible. RPCs have also proved to be very useful for muon track reconstruction
- …